DOI: 10.1111/bjd.15364 , , PMID: 28150889 Issn Print: 0007-0963 Publication Date: 2017/07/01 Print Facebook Twitter LinkedIn Email A phase I clinical trial demonstrates that nfP2X7‐targeted antibodies provide a novel, safe and tolerable topical therapy for basal cell carcinoma S.M. Gilbert; A. Gidley Baird; S. Glazer; J.A. Barden; A. Glazer; L.C. Teh; J. King + Author Information Author Information: Babraham Research Campus Biosceptre (U.K.) Limited Checking for direct PDF access through Ovid View on Journal Site Abstract Abstract unavailable for this article.